Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
Tri Juli Edi Tarigan,1 Adisti Dwijayanti,2 Susie Setyowati,3 Melva Louisa4 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Department of Medical Pharmacy, F...
Saved in:
Main Authors: | Tarigan TJE, Dwijayanti A, Setyowati S, Louisa M |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/e27ef62c838e4bd0b2b40e3c8d590d0a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
by: L. N. Shitov, et al.
Published: (2019) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009) -
Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
by: Nader ND, et al.
Published: (2020) -
Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
by: Irina A. Proskurina, et al.
Published: (2016)